Search research articles
Contact Us
Filters
Showing results (41-50 of 181) with videos related to
Page
of 19
Sort By:
Cancer
|
March 27, 2023
Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors
Shubham Pant, Erika Hamilton, Susanna V Ulahannan, et al.
ACS Applied Bio Materials
|
August 12, 2025
Dual Route Amine Functionalized Poly(l-lactic acid)/Mesoporous Bioactive Glass Based 3D Printed Composite Scaffolds: An Investigation on In Vitro and In Vivo Characteristics
Shubham Pant, Avinash Chaitanya Sagar Nakka, Devarathnam Jetty, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 28, 2025
CLO25-099: Lenvatinib With Pembrolizumab in Advanced Biliary Tract Cancer
Kabir Grewal, Shubham Pant, Ian Hu, et al.
The ... Text Retrieval Conference : TREC. Text Retrieval Conference
|
December 1, 2021
Overview of the TREC 2019 Precision Medicine Track
Kirk Roberts, Dina Demner-Fushman, Ellen M Voorhees, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 28, 2026
The SOS1 inhibitor BI 1701963 as monotherapy or in combination with trametinib in patients with KRAS mutation-positive solid tumors
Pasi A Jänne, Melissa L Johnson, Jin Li, et al.
Cancer Chemotherapy and Pharmacology
|
May 7, 2016
Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors
Johanna C Bendell, Manish R Patel, Kenichiro Yoshida, et al.
Journal of Gastrointestinal Oncology
|
March 17, 2020
Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia
Jane E Rogers, Jonathan D Mizrahi, Rachna T Shroff, et al.
Investigational New Drugs
|
August 21, 2024
Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer
Shubham Pant, Byoung Chul Cho, Christos E Kyriakopoulos, et al.
NPJ Precision Oncology
|
December 2, 2021
Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition
Niamh Coleman, Vivek Subbiah, Shubham Pant, et al.
Oral Oncology
|
October 1, 2016
PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck
Lori J Wirth, Shaker Dakhil, Gabriela Kornek, et al.
Page
of 19
Search research articles
Search
Showing results (41-50 of 181) with videos related to
Sort By:
Page
of 19
Cancer
|
March 27, 2023
Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors
Shubham Pant, Erika Hamilton, Susanna V Ulahannan, et al.
ACS Applied Bio Materials
|
August 12, 2025
Dual Route Amine Functionalized Poly(l-lactic acid)/Mesoporous Bioactive Glass Based 3D Printed Composite Scaffolds: An Investigation on In Vitro and In Vivo Characteristics
Shubham Pant, Avinash Chaitanya Sagar Nakka, Devarathnam Jetty, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 28, 2025
CLO25-099: Lenvatinib With Pembrolizumab in Advanced Biliary Tract Cancer
Kabir Grewal, Shubham Pant, Ian Hu, et al.
The ... Text Retrieval Conference : TREC. Text Retrieval Conference
|
December 1, 2021
Overview of the TREC 2019 Precision Medicine Track
Kirk Roberts, Dina Demner-Fushman, Ellen M Voorhees, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 28, 2026
The SOS1 inhibitor BI 1701963 as monotherapy or in combination with trametinib in patients with KRAS mutation-positive solid tumors
Pasi A Jänne, Melissa L Johnson, Jin Li, et al.
Cancer Chemotherapy and Pharmacology
|
May 7, 2016
Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors
Johanna C Bendell, Manish R Patel, Kenichiro Yoshida, et al.
Journal of Gastrointestinal Oncology
|
March 17, 2020
Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia
Jane E Rogers, Jonathan D Mizrahi, Rachna T Shroff, et al.
Investigational New Drugs
|
August 21, 2024
Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer
Shubham Pant, Byoung Chul Cho, Christos E Kyriakopoulos, et al.
NPJ Precision Oncology
|
December 2, 2021
Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition
Niamh Coleman, Vivek Subbiah, Shubham Pant, et al.
Oral Oncology
|
October 1, 2016
PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck
Lori J Wirth, Shaker Dakhil, Gabriela Kornek, et al.
Page
of 19